PPT-Clonal Evolution in CLL:

Impact on t iming of therapy Nicholas Chiorazzi The Feinstein Institute for Medical Research North Shore LIJ Health System Manhasset NY At all points in time CLL clones are heterogeneous based on a number of criteria. Diagnostic Slide Session. AANP - Annual Meeting. Saturday, June 23, 2012. David Pisapia, M.D.. Neuropathology Fellow. Department of Pathology & Cell Biology. Clinical History. 5/2010. CLL. 67-year-old woman. composition . of . a breast . cancer . from multiple tissue samples. Habil Zare. Department of Genome Sciences. University of Washington. 19 Dec 2013. 1. Hypothesis. Because cancer is a heterogeneous disease, synergistic medications can treat it better than a single drug.. Ibrutinib. Sensitivity and Resistance in CLL. Y. Lynn Wang, MD, PhD, FCAP. Dept. of Pathology. University of Chicago. October 24, 2014. Outline. Ibrutinib. targets . in vivo CLL proliferation through . New agents timing?. Agne Paner, MD. Assistant professor of Medicine. RUSH University Medical Center. Blood Smear in CLL. Chronic Lymphocytic Leukemia. Most prevalent type of adult leukemia . 30% of all . CLL/SLL. Use of Markers in Nonclinical Trial Practice. CLL/SLL. Frontline Therapy. CLL/SLL. Second-line Therapy. CLL/SLL. Cure vs Indefinite Therapy. CLL/SLL. CART-19 Therapy. Neil E Kay, M.D.. October 2014. Mayo Team. Deb Bowen. Tim Call. Michael Conte. Wei Ding. Tait Shanafelt. Steve Ansell. Learning Objectives. Review “standard therapies” of WM and CLL. C. an we still consider standard therapies in WM and CLL?. IWCLL Criteria for Treating CLL. Other Considerations at Relapse. Risk Factors at Relapse. IGHV . Status Affects Clinical Course. Case 1: 65-Year-Old Man. Assessing This Patient's Options. TP53 . Mutation/del(17p) and CIT. Jennifer R Brown, MD PhD. Director, CLL Center. Dana-Farber Cancer Institute. October 24, 2014. What is High Risk CLL? . Historically defined solely by clinical features:. Stage, lymphocyte doubling time, . Mary-Margaret Allen, MD. February 24, 2015. 58 . yo. male with a history of CLL (2008). Later developed AIHA 2/2013. P. rednisone taper (Feb to May 2013). Recurrent 9/2013: . rituxan. and quick steroid taper. δ. ) Inhibitor, . Idelalisib. (GS-1101) in Combination with Rituximab and/or . Bendamustine. in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL. ). Coutre. SE et al.. Proc. leukemia. Magdalena Olszewska-Szopa. Definition. Chronic. . lymphocytic. leukemia (CLL) . belongs. to B-. cell. . low-grade. . non-. Hodgkin. . lymphomas. . . CLL . is. the. . most common . form of leukemia in adults.. Limited,Venetoclax. -Based and Continuous Bruton . Thyrosine. Kinase Inhibitors-Based Therapy in the Upfront Treatment of Chronic Lymphocytic Leukemia (CLL):a Systematic Review and Network Meta-Analysis. Supervisor: VS . 曾主任. Cell 152, 714–726, February 14, 2013. Chronic lymphocytic leukemia. CLL. Mature B lymphocyte ≧ 5000/. uL. in the peripheral blood. M. onoclonal B-. lymphocytosis. Mature B lymphocyte < 5000/. Pan - London Haemato - O ncology Clinical G Lymphoid M alignancies Part 4: Chronic Lymphocytic Leuk a emia (CLL) and B - prolymphocytic L eukaemia (B - PLL ) January 2020 CONTENTS 2 Contents 1 Introd